- Home
- APLM vs APCX Comparison
APLM vs APCX Comparison
Compare APLM & APCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- APCX
- Stock Information
- Founded
- APLM 2016
- APCX 2006
- Country
- APLM United States
- APCX United States
- Employees
- APLM N/A
- APCX N/A
- Industry
- APLM Blank Checks
- APCX Finance: Consumer Services
- Sector
- APLM Finance
- APCX Finance
- Exchange
- APLM Nasdaq
- APCX Nasdaq
- Market Cap
- APLM 15.6M
- APCX 15.8M
- IPO Year
- APLM N/A
- APCX N/A
- Fundamental
- Price
- APLM $0.16
- APCX $0.56
- Analyst Decision
- APLM Strong Buy
- APCX
- Analyst Count
- APLM 2
- APCX 0
- Target Price
- APLM $4.25
- APCX N/A
- AVG Volume (30 Days)
- APLM 924.9K
- APCX 279.0K
- Earning Date
- APLM 08-14-2024
- APCX 11-12-2024
- Dividend Yield
- APLM N/A
- APCX N/A
- EPS Growth
- APLM N/A
- APCX N/A
- EPS
- APLM N/A
- APCX N/A
- Revenue
- APLM $2,101,000.00
- APCX $462,000.00
- Revenue This Year
- APLM N/A
- APCX $1,315.48
- Revenue Next Year
- APLM N/A
- APCX N/A
- P/E Ratio
- APLM N/A
- APCX N/A
- Revenue Growth
- APLM 70.54
- APCX 3.59
- 52 Week Low
- APLM $0.11
- APCX $0.44
- 52 Week High
- APLM $3.18
- APCX $3.36
- Technical
- Relative Strength Index (RSI)
- APLM 60.35
- APCX 32.74
- Support Level
- APLM $0.13
- APCX $0.44
- Resistance Level
- APLM $0.18
- APCX $0.62
- Average True Range (ATR)
- APLM 0.01
- APCX 0.08
- MACD
- APLM 0.00
- APCX -0.01
- Stochastic Oscillator
- APLM 65.52
- APCX 24.85
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.